Computational screening of FDA-approved hepatitis c drugs for inhibition of VEGFR2 in liver cancer

Computational screening of FDA-approved hepatitis c drugs for inhibition of VEGFR2 in liver cancer

Liver cancer (LC) is one of the most common tumours and the leading cause of cancer-related death globally. Amidst the problems associated with existing treatments, such as hepatotoxicity, recurrence, drug resistance, and other adverse effects, researchers are under pressure to find alternatives. To...

Full description

Bibliographic Details
Main Authors: Roney, Miah, Issahaku, Abdul Rashid, Tufail, Nasir, Wilhelm, Anke, Mohd Fadhlizil Fasihi, Mohd Aluwi
Format: Article
Language:English
Published: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim 2024
Subjects:
HD Industries. Land use. Labor
Online Access:http://umpir.ump.edu.my/id/eprint/43151/
http://umpir.ump.edu.my/id/eprint/43151/1/Computational%20Screening%20of%20FDA-Approved%20Hepatitis%20C.pdf

Internet

http://umpir.ump.edu.my/id/eprint/43151/
http://umpir.ump.edu.my/id/eprint/43151/1/Computational%20Screening%20of%20FDA-Approved%20Hepatitis%20C.pdf

Similar Items